CANTA Cantargia AB (publ)
1.420SEK-4.05%Mkt Cap: 33.77M $P/E: 2.09Today
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind I…
Industry Peers
Biotechnology$127.24BUSDP/E 29.3
$76.05BUSDP/E 18.3
$74.84BUSD
$56.77BUSDP/E 37.1
$58.21BUSDP/E 35.5
$41.93BUSDP/E 17.9
$42.84BUSD
$41.27BUSDP/E 64.9
$32.61BUSDP/E 30.0
$29.97BUSDP/E 37.8
$25.66BUSD
$24.05BUSD
$23.24BUSDP/E 29.8
$22.98BUSD
$22.23BUSDP/E 30.6
$22.85BUSDP/E 14.4
$15.02BUSDP/E 15.9
$14.87BUSDP/E 17.3
$14.45BUSDP/E 18.4
$13.81BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Cantargia AB (FRA:7V3) (Q2 2026) Earnings Call Highlights: Strong Cash Position and Promising ... Company reports complete remission in all evaluable high-risk MDS patients and secures funding to extend runway into mid-2028. | ||